永顺生物
(920729)
| 流通市值：4.77亿 | | | 总市值：16.84亿 |
| 流通股本：7750.70万 | | | 总股本：2.73亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 133,353,482.5 | 87,485,096.54 | 47,452,322.97 | 238,174,536.39 |
| 营业总成本 | 134,353,971.89 | 84,702,179.66 | 43,338,273.37 | 206,942,003.57 |
| 其他经营收益 | | | | |
| 营业利润 | 5,061,015.19 | 6,562,085.49 | 5,378,870.13 | 46,290,370.35 |
| 利润总额 | 5,328,039.19 | 6,741,928.49 | 5,412,144.78 | 46,195,892.78 |
| 净利润 | 5,794,173.77 | 6,414,601.68 | 5,083,098.81 | 41,257,977.62 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 5,794,173.77 | 6,414,601.68 | 5,083,098.81 | 41,257,977.62 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 383,651,302.05 | 400,341,350.67 | 269,250,866.9 | 293,154,987.07 |
| 非流动资产: | | | | |
| 非流动资产合计 | 363,309,343.69 | 349,264,924.96 | 525,038,311.44 | 500,700,529.12 |
| 资产总计 | 746,960,645.74 | 749,606,275.63 | 794,289,178.34 | 793,855,516.19 |
| 流动负债: | | | | |
| 流动负债合计 | 86,668,671.82 | 88,611,004.72 | 105,878,134.82 | 111,316,290.98 |
| 非流动负债: | | | | |
| 非流动负债合计 | 5,716,698.67 | 6,636,966.9 | 6,976,141.51 | 6,875,849.61 |
| 负债合计 | 92,385,370.49 | 95,247,971.62 | 112,854,276.33 | 118,192,140.59 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 654,575,275.25 | 654,358,304.01 | 681,434,902.01 | 675,663,375.6 |
| 股东权益合计 | 654,575,275.25 | 654,358,304.01 | 681,434,902.01 | 675,663,375.6 |
| 负债和股东权益合计 | 746,960,645.74 | 749,606,275.63 | 794,289,178.34 | 793,855,516.19 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 147,791,031.99 | 98,572,863.08 | 50,727,467.76 | 277,217,012.02 |
| 经营活动现金流出小计 | 132,240,957.03 | 95,664,996.87 | 50,437,877.18 | 177,184,316.61 |
| 经营活动产生的现金流量净额 | 15,550,074.96 | 2,907,866.21 | 289,590.58 | 100,032,695.41 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 551,824,091.83 | 392,402,352.94 | 186,166,395.15 | 361,110,466.91 |
| 投资活动现金流出小计 | 490,568,926 | 339,680,102 | 162,238,200 | 457,540,495.9 |
| 投资活动产生的现金流量净额 | 61,255,165.83 | 52,722,250.94 | 23,928,195.15 | -96,430,028.99 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 495,984.32 | 495,984.32 | 495,984.32 | 15,514,413.62 |
| 筹资活动现金流出小计 | 36,202,087.95 | 35,850,890.36 | 157,695.18 | 36,166,424.8 |
| 筹资活动产生的现金流量净额 | -35,706,103.63 | -35,354,906.04 | 338,289.14 | -20,652,011.18 |
| 汇率变动对现金及现金等价物的影响 | -1,199,424.53 | -779,574.04 | -324,759.84 | -153,330.43 |
| 现金及现金等价物净增加额 | 39,899,712.63 | 19,495,637.07 | 24,231,315.03 | -17,202,675.19 |
| 期末现金及现金等价物余额 | 59,137,611.62 | 38,733,536.06 | 43,469,214.02 | 19,237,898.99 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 19,495,637.07 | - | -17,202,675.19 |